United Therapeutics (UTHR) EBITDA (2009 - 2026)

United Therapeutics (UTHR) has 18 years of EBITDA data on file, last reported at $325.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 14.89% year-over-year to $325.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 2.28% YoY), and the FY2025 full-year result was $1.5 billion, up 8.39% from the prior year.
• EBITDA fell to $325.8 million in Q1 2026, from $356.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $388.5 million in Q3 2025 to a low of $175.6 million in Q4 2022.
• A 5-year average of $315.3 million and a median of $325.8 million in 2026 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 544.44% in 2022 and slipped 14.89% in 2026, its largest moves.
• Tracing UTHR's EBITDA over 5 years: stood at $175.6 million in 2022, then surged by 48.12% to $260.1 million in 2023, then soared by 37.52% to $357.7 million in 2024, then decreased by 0.28% to $356.7 million in 2025, then decreased by 8.66% to $325.8 million in 2026.
• Business Quant data shows UTHR's EBITDA at $325.8 million in Q1 2026, $356.7 million in Q4 2025, and $388.5 million in Q3 2025.